Home Cart Sign in  
Chemical Structure| 475085-57-5 Chemical Structure| 475085-57-5

Structure of MRE-269
CAS No.: 475085-57-5

Chemical Structure| 475085-57-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MRE-269 can act as an agonist of IP receptor and it is an active metabolite of selexipag.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MRE-269

CAS No. :475085-57-5
Formula : C25H29N3O3
M.W : 419.52
SMILES Code : O=C(O)COCCCCN(C1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)N=C1)C(C)C
MDL No. :MFCD11976884
InChI Key :OJQMKCBWYCWFPU-UHFFFAOYSA-N
Pubchem ID :9931891

Safety of MRE-269

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of MRE-269

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Rat mesenteric artery smooth muscle cells 0.01–1 μmol/L To investigate the IP receptor-mediated vasorelaxation by MRE-269 and its dependence on KV7.1 channels. Results showed that MRE-269 induced vasorelaxation via IP receptor activation, which was significantly attenuated by the KV7.1 inhibitor HMR-1556. Br J Pharmacol. 2022 Apr;179(7):1338-1352
human lung fibroblasts 1 μM 30 min MRE-269 caused a sustained increase in nuclear cAMP and complete inhibition of PDGF-induced nuclear ERK and fibroblast proliferation. Front Pharmacol. 2021 Apr 29;12:669227

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Aged male Sprague-Dawley rats Transient middle cerebral artery occlusion (MCAO) model Intravenous injection 0.25 mg/kg Initial administration started at 4.5 h post-ischemia, with additional doses every 12 h for the first 48 h, then once daily for 7 days MRE-269 significantly reduced infarct volume, improved long-term neurological recovery, reduced inflammation and oxidative stress, and protected the blood-brain barrier Stroke. 2017 Jul;48(7):1948-1956
Aged male Sprague-Dawley rats Transient middle cerebral artery occlusion (MCAO) model Intravenous injection 0.25 mg/kg Initial dose at 4.5 h post-ischemia, followed by doses every 12 h for the first 48 h, then once daily for 7 days To evaluate the long-term neuroprotective effects of MRE-269 in ischemic stroke. Results showed that MRE-269 significantly reduced infarct volume, improved long-term recovery of locomotor and somatosensory functions, reduced body weight loss, decreased pro-inflammatory cytokines/chemokines and oxidative stress, and reduced BBB damage and MMP-9 activity. Stroke. 2017 Jul;48(7):1948-1956
Wistar rats Male and female rat mesenteric arteries In vitro, administered via wire-myograph 0.01–1 μmol/L Single dose, duration not specified To investigate the vasorelaxant effects of MRE-269 in male and female rat mesenteric arteries and its underlying mechanisms. Results demonstrated that MRE-269 induced vasorelaxation via IP receptor activation, which was significantly attenuated by the KV7.1 inhibitor HMR-1556, indicating a critical role of KV7.1 channels in IP receptor-mediated vasorelaxation. Additionally, female rats in pro-oestrus/oestrus showed reduced responsiveness to MRE-269. Br J Pharmacol. 2022 Apr;179(7):1338-1352

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.38mL

0.48mL

0.24mL

11.92mL

2.38mL

1.19mL

23.84mL

4.77mL

2.38mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories